help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-1631
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/4/1319    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaplan, R. C.
Right arrow Articles by Psaty, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaplan, R. C.
Right arrow Articles by Psaty, B. M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Cardiovascular Endocrinology
Right arrow Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 4 1319-1325
Copyright © 2007 by The Endocrine Society

Association of Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1), and IGFBP-3 Levels with Incident Coronary Events and Ischemic Stroke

Robert C. Kaplan, Aileen P. McGinn, Michael N. Pollak, Lewis H. Kuller, Howard D. Strickler, Tom E. Rohan, Anne R. Cappola, XiaoNan Xue and Bruce M. Psaty

Department of Epidemiology and Population Health (R.C.K., A.P.M., H.D.S., T.E.R., X.X.), Albert Einstein College of Medicine, Bronx, New York 10461; Cancer Prevention Research Unit, Departments of Medicine and Oncology (M.N.P.), Lady Davis Research Institute of Jewish General Hospital and McGill University, Montreal, Quebec, Canada H3T 1E2; Department of Medicine and Epidemiology (L.H.K.), University of Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine (A.R.C.), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; and Departments of Epidemiology, Medicine and Health Services, Cardiovascular Health Research Unit (B.M.P.), University of Washington, Seattle, Washington 98101

Address all correspondence and requests for reprints to: Robert C. Kaplan, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Belfer 1306C, Bronx, New York 10461. E-mail: rkaplan{at}aecom.yu.edu.

Context: Prior observational studies have demonstrated that the GH/IGF axis is associated with cardiovascular disease. However, this association has not been extensively studied among older adults.

Objective: The objective of this study was to assess the association between levels of total IGF-I and IGF binding proteins (IGFBP-1, IGFBP-3) and risk of incident coronary events and ischemic stroke.

Design and Participants: A case-cohort analysis was conducted among adults 65 yr and older in the Cardiovascular Health Study.

Main Outcome Measures: A total of 534 coronary events [316 nonfatal myocardial infarctions (MIs), 48 fatal MIs, and 170 fatal coronary heart disease events] and 370 ischemic strokes were identified on follow-up. Comparison subjects were 1122 randomly selected participants from the Cardiovascular Health Study.

Results: Mean follow-up time was 6.7 yr for coronary events, 5.6 yr for strokes, and 9.3 yr for comparison subjects. Hazard ratios (95% confidence intervals) associated with baseline levels of total IGF-I and IGFBPs were estimated using multivariate adjusted Cox proportional hazards models. Neither IGF-I nor IGFBP-1 levels predicted risk of incident coronary events or stroke. IGFBP-3 had an inverse association with risk of coronary events [adjusted hazard ratio per SD = 0.88 (0.78–1.00), P = 0.05] but was not associated with stroke. Exploratory analyses suggested that low IGF-I and low IGFBP-3 levels were significantly associated with higher risk of nonfatal MI (P < 0.05) but not with risk of fatal MI or fatal coronary heart disease.

Conclusion: Circulating levels of total IGF-I or IGFBP-1 were not associated with risk of total coronary events or ischemic stroke among older adults, whereas low IGFBP-3 level was associated with increased risk of incident coronary events.




This article has been cited by other articles:


Home page
Clin. Chem.Home page
J. H. Page, J. Ma, M. Pollak, J. E. Manson, and S. E. Hankinson
Plasma Insulinlike Growth Factor 1 and Binding-Protein 3 and Risk of Myocardial Infarction in Women: A Prospective Study
Clin. Chem., October 1, 2008; 54(10): 1682 - 1688.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Perticone, A. Sciacqua, M. Perticone, I. Laino, S. Miceli, I. Care', G. Galiano Leone, F. Andreozzi, R. Maio, and G. Sesti
Low-Plasma Insulin-Like Growth Factor-I Levels Are Associated with Impaired Endothelium-Dependent Vasodilatation in a Cohort of Untreated, Hypertensive Caucasian Subjects
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2806 - 2810.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society